Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HM 15136

Drug Profile

HM 15136

Alternative Names: LAPSGlucagon Analog; HM-15136

Latest Information Update: 09 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antihypoglycaemics; Obesity therapies; Pancreatic hormones
  • Mechanism of Action Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital hyperinsulinism; Autoimmune disorders
  • New Molecular Entity No

Highest Development Phases

  • Phase II Congenital hyperinsulinism
  • Preclinical Obesity

Most Recent Events

  • 15 Jun 2023 Pharmacodynamics data from a preclinical trial in Hyperinsulinaemia presented at the 105th Annual Meeting of the Endocrine Society (ENDO-2023)
  • 11 Nov 2022 pharmacodynamic data of HM 15136 in obesity presented at 58th Annual Meeting of the European Association for the Study of Diabetes (EASD-2022)
  • 17 Jun 2022 Hanmi Pharmaceutical receives Rare paediatric disease designation from the US FDA in Congenital-hyperinsulinism before June 2022 (Hanmi Pharmaceutical pipeline, June 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top